Plasma and plasma derivatives in therapeutic plasmapheresis (Q38009419)

26 August 2017

title

Plasma and plasma derivatives in therapeutic plasmapheresis (English)

1 reference

26 August 2017

Bruce C McLeod

1 reference

26 August 2017

publication date

1 May 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

52 Suppl 1

1 reference

26 August 2017

page(s)

38S-44S

1 reference

Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

Production of human albumin solution: a continually developing colloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

Safety of human albumin as a constituent of biologic therapeutic products

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

Pyrogen reactions to human serum albumin during plasma exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

Human albumin administration in critically ill patients: systematic review of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

A comparison of albumin and saline for fluid resuscitation in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

Frequency of immediate adverse effects associated with therapeutic apheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

Adverse events and problems in therapeutic hemapheresis. A report from the Swedish registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

Apheresis registry in France: indications, techniques, and complications. French Registry Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6°C storage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

Metabolic alkalosis due to plasmapheresis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

Therapeutic apheresis in renal and metabolic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03623.X

10.1111/J.1537-2995.2012.03623.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference